Small-molecule PD-1/PD-L1 inhibitor HY19991 (structure shown in Figure S1A, ESI) was used in this study, which cuts off the interaction of PD-1/PD-L1 between T cells and tumor cells, resulting in the activation of T cells 28-30. The gene discussed is PDCD1; the disease is neoplasm.